NCT07004335View on ClinicalTrials.gov

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

January 31, 2029

Conditions
PD-(L)1CTLA-4Advanced MelanomaIparomlimabTuvonralimabBevacizumab
Interventions
DRUG

Iparomlimab and Tuvonralimab Injection plus Bevacizumab

The experimental group will receive intravenous infusion of anti PD-1/CTLA-4 (Iparomlimab/Tuvonralimab) Injection (5 mg/kg) and Bevacizumab (dose 7.5mg/kg) once every 3 weeks up to 35 cycles (105 weeks).

Trial Locations (1)

Unknown

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Hebei Medical University Fourth Hospital

OTHER